Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction -
AE Schade, G Gonzalez-Stawinski - 2008 - ingentaconnect.com
... [31-35] BMS-354825 Dasatinib; Sprycel 0.4 Approved for: CML, Philadelphia
chromosome positive ALL ... Annu. Rev. Immunol., 1999, 17, 467-522. ...
On the iTRAQ of kinase inhibitors -
FM White - Nature Biotechnology, 2007 - nature.com
... The other two, dasatanib (Sprycel) 8 and bosutinib 9 , both of which target ABL-
and SRC-family kinases, are used to treat patients with ... 214, 459?467 (1993). ...
Extra navigation
TK Sawyer, NPG Contact - nature.com
... (a) Sprycel (dasatinib), an active conformation?binding inhibitor. (b) Gleevec,
an inactive conformation?binding inhibitor. ... Biol. 9, 467?474 (2005). ...
Dasatinib: In Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic … -
SJ Keam - BioDrugs, 2008 - biodrugs.adisonline.com
... Dasatinib (Sprycel?)1, a small-molecule carboxamide derivative (structurally unrelated
to imatinib ... method (QTcF) was prolonged in 9 of 467 patients receiving ...
METABOLITE GENERATION VIA MICROBIAL BIOTRANSFORMATIONS WITH ACTINOMYCETES: RAPID SCREENING FOR … -
W Li, JL Josephs, GL Skiles, G Humphreys - Drug Metabolism and Disposition, 2008 - ASPET
... drug candidates under development, BMS-587101 and dasatinib (SPRYCEL ? ,
BMS- ... ( SPRYCEL ? , BMS- 345825, Figure 2), is described. ...
-
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges -
DA Thomas - Hematology, 2007 - asheducationbook.hematologylibrary.org
... Second-generation TKIs such as dasatinib (BMS-354825; SPRYCEL; Bristol-Myers Squibb ...
2006;38:467?475.[CrossRef][Medline]; Schindler T, Bornmann W, Pellicena P ...
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated … -
SH Xiao, E Farrelly, J Anzola, D Crawford, XY Jiao … - Analytical Biochemistry, 2007 - Elsevier
... PDFR-? inhibitor Nexavar (sorafenib, codeveloped by Onyx and Bayer) and the multiple
kinase inhibitors Sutent (SU11248, Pfizer) and Sprycel (dasatinib, Bristol ...
Molecularly Targeted Therapy for Malignant Glioma -
S Sathornsumetee, DA Reardon, A Desjardins, JA … - MD - doi.wiley.com
Page 1. Molecularly Targeted Therapy for Malignant Glioma Sith Sathornsumetee,
MD 1,2 David A. Reardon, MD 1,3 Annick Desjardins, MD ...
State-of-the-art in the treatment of chronic myeloid leukaemia. -
D Milojkovic, J Apperley - Current Opinion in Oncology, 2008 - co-oncology.com
... Dasatinib (Sprycel; BMS 354825) is a dual Src/Abl kinase inhibitor that binds to
the Abl kinase domain irrespective of the configuration of the activation loop ...
[PDF] Chronic Myeloid Leukemia: Current Management Challenges
E Atallah, H Kantarjian, J Cortes, S Giralt, T … - hememalignancies.com
Page 1. Editors-in-Chief James O. Armitage Bruce D. Cheson Sundar Jagannath
Vinay K. Jain Full Text Now Online At www.clinicallymphoma.com ...
Source: Google Scholar |
